Junshi Biosciences - Coherus Toripalimab Chemo Combo Met Survival Endpoints In Lung Cancer Setting

Junshi Biosciences - Coherus Toripalimab Chemo Combo Met Survival Endpoints In Lung Cancer Setting
  • Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc CHRS have shared biomarker analyses from the CHOICE-01 Phase 3 trial of toripalimab plus chemotherapy as first-line treatment of advanced squamous or non-squamous non-small cell lung cancer (NSCLC). 
  • As of October 31, 2021, at the final analysis, a significant improvement in PFS was detected in the toripalimab arm over the placebo arm, with a median PFS of 8.4 vs. 5.6 months. 
  • The 1-year PFS rates for the toripalimab and placebo arms were 36.7% and 17.2%, respectively.
  • Related: Junshi Biosciences, Coherus Share Toripalimab Survival Data In Esophageal Cancer.
  • A prespecified interim analysis demonstrated a statistically significant improvement in overall survival for the toripalimab arm over the placebo arm (median OS not reached vs. 17.1 months).
  • The addition of toripalimab to standard first-line chemotherapy in patients with advanced NSCLC showed a manageable safety profile with no new safety signals observed. 
  • Price Action: CHRS shares are up 5.51% at $12.73 during the market session on the last check Tuesday.

Posted In: BriefsNon-Small Cell Lung CancerPhase 3 TrialBiotechNewsHealth CareSmall CapMoversTrading IdeasGeneral